VivoSeq
Oncology

Soft Tissue Sarcoma

217

Pipeline Programs↗

74

Active Trials↗

87

Companies Involved↗

Soft Tissue Sarcoma is a highly competitive landscape with 217 programs across 87 companies. The most active players are CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Presage Biosciences, Base Therapeutics (Shanghai) Co., Ltd.. 7 therapies are approved with 27 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

83/100

Pipeline Velocity

42/100

Mech. Concentration

9/100

Completion Rate

79/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

1 program

Phase 1P

Presage Biosciences

1 program

Phase 1B

Base Therapeutics (Shanghai) Co., Ltd.

1 program

Phase 1Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

Phase 1Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

1 program

Phase 1E

Essen Biotech

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical6

Olaratumab

Eli Lilly

Doxil

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Piamprimab (AK105)

Henan Cancer Hospital

Fluorodopa F 18

Mayo Clinic

Anrotinib

Henan Cancer Hospital

Phase 140

Mitoxantrone Hydrochloride

Pfizer

Lurbinectedin

Jazz Pharmaceuticals

Dexamethasone

Aspen Global Incorporated

Aminolevulinic Acid

Biomed Industries, Inc.

Ribociclib

Novartis

Phase 2137

Regorafenib

Bayer

Camrelizumab

Sun Yat-sen University

Surufatinib

Hutchison Medipharma Limited

Fluzoparib

Risen (Suzhou) Pharma Tech Co., Ltd.

Atezolizumab

Roche

Phase 327

Docetaxel

Avyxa

Eribulin Mesylate

Eisai

Ridaforolimus

Merck & Co.

Ezabenlimab

Boehringer Ingelheim

Cyclophosphamide

Baxter Healthcare Corporation

Approved7

Panobinostat

SecuraBio

Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Olaparib

AstraZeneca

Idarubicin

Pfizer

Bendamustine

Azurity Pharmaceuticals

Analysis

Modality Breakdown

84%

Small molecule

207 of 245 classified programs — the dominant modality here.

16%ALL OTHERSMonoclonal antibody239%Protein / enzyme83%Cell therapy42%Vaccine2<1%Gene therapy1<1%

Small molecule leads; the ring shows all 245 classified programs, each share of the total. Modality classified for 100% of 259 pipeline programs.

Analysis

Trial Status

324

clinical trials

Completed160 · 49%
Unknown status45 · 14%
Recruiting42 · 13%
Terminated31 · 10%
Active, not recruiting20 · 6%
Not yet recruiting12 · 4%
Other14 · 4%

Clinical Trials

Trial Activity

324 trials

89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma
Recruiting·TTelix Pharmaceuticals (Innovations) Pty Ltd·Phase 1·NCT06537596·50 enrolled
Pemetrexed, Cisplatin With Soft Tissue Sarcoma
Recruiting·YYonsei University·Phase 2·NCT04605770·164 enrolled
The Total Neoadjuvant Therapy for Soft Tissue Sarcoma of the Extremities
Recruiting·FFujian Medical University Union Hospital·Phase 2·NCT06593899·51 enrolled
Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma
Recruiting·IInstitut Claudius Regaud·Phase 3·NCT04307277·600 enrolled
Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
Recruiting·CCNBG-Virogin Biotech (Shanghai) Ltd.·Phase 2·NCT06126510·40 enrolled
QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
Recruiting·SSun Yat-sen University·Phase 2·NCT06939855·45 enrolled
Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study
Recruiting·—·Phase 4·NCT03144206·20 enrolled
Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma.
Recruiting·—·Phase 2·NCT06514313·110 enrolled
Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma
Recruiting·OOslo University Hospital·Phase 2·NCT04776525·49 enrolled
A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma
Recruiting·—·Phase 3·NCT04650984·102 enrolled
Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)
Recruiting·SSwiss Cancer Institute·Phase 2·NCT06835049·24 enrolled
Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma
Recruiting·SShenzhen University General Hospital·N/A·NCT05620693·20 enrolled
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07049848·50 enrolled
A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06367075·53 enrolled
Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Recruiting·WWake Forest University Health Sciences·Phase 2·NCT07291297·50 enrolled
Page 1 of 22

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)